You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Eye conditions

Bevacizumab gamma for treating wet age-related macular degeneration

  • Technology appraisal guidance
  • Reference number: TA1022
  • Published:  04 December 2024
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Final draft guidance
  2. Invitation to participate
  3. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6320

History

Documents created during the development process.

Final draft guidance

  • Final draft guidance

  • Final draft guidance (PDF 133 KB)

    Published:
    31 October 2024
  • Committee papers (PDF 4.1 MB)

    Published:
    31 October 2024
  • Equality impact assessment (downloadable version) (PDF 121 KB)

    Published:
    31 October 2024

Invitation to participate

  • Final scope (PDF 187 KB)

    Published:
    20 June 2024
  • Final stakeholder list (PDF 171 KB)

    Published:
    20 June 2024
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 349 KB)

    Published:
    20 June 2024
  • Equality impact assessment (Scoping) (PDF 124 KB)

    Published:
    20 June 2024

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6320

  • Draft matrix post referral (PDF 173 KB)

    Published:
    01 March 2024
  • Draft scope post referral (PDF 201 KB)

    Published:
    01 March 2024
Back to top